AcelRx Pharmaceuticals Inc. (ACRX) Receives Consensus Rating of “Hold” from Analysts
Shares of AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) have been assigned an average rating of “Hold” from the ten research firms that are covering the firm. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $8.20.
Several equities research analysts have commented on the stock. Roth Capital set a $15.00 target price on shares of AcelRx Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday. Cowen and Company reaffirmed a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Friday, July 29th. RBC Capital Markets reaffirmed a “positive” rating and issued a $6.00 target price on shares of AcelRx Pharmaceuticals in a research note on Tuesday, August 16th. Stifel Nicolaus downgraded shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of AcelRx Pharmaceuticals in a research note on Monday, August 1st.
AcelRx Pharmaceuticals (NASDAQ:ACRX) traded down 0.746% during midday trading on Monday, hitting $3.325. 49,562 shares of the company traded hands. The stock’s 50-day moving average is $3.49 and its 200-day moving average is $3.32. The firm’s market capitalization is $150.66 million. AcelRx Pharmaceuticals has a 12-month low of $2.40 and a 12-month high of $5.88.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/acelrx-pharmaceuticals-inc-acrx-receives-consensus-rating-of-hold-from-analysts.html
AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its earnings results on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by $0.02. AcelRx Pharmaceuticals had a negative net margin of 111.47% and a negative return on equity of 94.98%. The firm earned $4.53 million during the quarter, compared to the consensus estimate of $2.17 million. Analysts anticipate that AcelRx Pharmaceuticals will post ($0.93) EPS for the current fiscal year.
In related news, major shareholder Perceptive Advisors Llc sold 216,500 shares of the firm’s stock in a transaction on Thursday, September 29th. The shares were sold at an average price of $3.92, for a total value of $848,680.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 27.40% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in the stock. State Street Corp boosted its stake in shares of AcelRx Pharmaceuticals by 2,427.4% in the second quarter. State Street Corp now owns 424,598 shares of the specialty pharmaceutical company’s stock worth $1,142,000 after buying an additional 407,798 shares in the last quarter. Advisor Group Inc. purchased a new stake in shares of AcelRx Pharmaceuticals during the second quarter worth approximately $355,000. Rhumbline Advisers purchased a new stake in shares of AcelRx Pharmaceuticals during the second quarter worth approximately $103,000. Teachers Advisors Inc. purchased a new stake in shares of AcelRx Pharmaceuticals during the second quarter worth approximately $157,000. Finally, BlackRock Institutional Trust Company N.A. boosted its stake in shares of AcelRx Pharmaceuticals by 73.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 962,026 shares of the specialty pharmaceutical company’s stock worth $2,588,000 after buying an additional 406,974 shares in the last quarter. Hedge funds and other institutional investors own 35.85% of the company’s stock.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.